TrialAnnals of hematology2021

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.

Richard Greil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.